Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Background: There is no standard second-line treatment for advanced urothelial carcinoma (UC). Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC. Patients and methods: Treatment...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Oncol
Hlavní autoři: Rosenberg, J. E., Halabi, S., Sanford, B. L., Himelstein, A. L., Atkins, J. N., Hohl, R. J., Millard, F., Bajorin, D. F., Small, E. J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2008
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815560/
https://ncbi.nlm.nih.gov/pubmed/18272914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdm600
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky